Spontaneous closure of FTMH after vitrectomy for VMT

Article

In this article, the authors summarize a recently published case study of a macular hole formation and its spontaneous closure after vitrectomy.

In our clinic we experienced a case of a macular hole formation and its spontaneous closure after vitrectomy for VMT, which we have recently published.1 In this article, we will present a brief summary of this case report and our findings.

Case presentation

A week after vitrectomy we found, using SD-OCT examination (Spectralis, Heidelberg Engineering, Heidelberg, Germany), that the VMT had resolved but a full-thickness macular hole (FTMH) had formed. A month later the FTMH had spontaneously closed, and after another 5 months, SD-OCT showed a normal foveal contour.

First description

The current case is, to the best of our knowledge, the first description of macular hole formation and spontaneous closure after vitrectomy for VMT that is clearly documented step-by-step with SD-OCT.

The formation of FTMH may have been a result of the creation of anterio-posterior traction on the fovea by the posterior hyaloid membrane, in addition to, damage caused to the retinal layer in the macular area during detachment.

In this case, the traction was pulled up to the retina, so that the edges of the hole were elevated high, but it was stabilized by the ILM and the posterior hyaloid membrane during surgically induced detachment. The complex of the posterior hyaloid membrane and ILM was probably removed in the macular area and FTMH developed.

Conclusion

FTMH may develop in its natural course and after vitrectomy for VMT.2,3 However, in these referenced cases there was no spontaneous closure of the FTHM, they all required further surgery to close the macular hole.

The release of the mechanical traction may be the main reason for the eventual closure of the macular hole. However, ILM peeling induces glial cell proliferation across the hole and this mechanism may also help the spontaneous closure of macular hole.

References

1. D. Odrobina et al., BMC Ophthalmology, 2014;14:17.

2. N. Yamada et al., Am. J. Ophthalmol., 2005;139(1):112–117.

3. D. Odrobina et al., Retina, 2011;31(2):324–331.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.